Aerie Pharmaceuticals, Inc. (AERI)
(Delayed Data from NSDQ)
$39.78 USD
+1.23 (3.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.78 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AERI 39.78 +1.23(3.19%)
Will AERI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AERI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AERI
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
AERI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
The Zacks Analyst Blog Highlights SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals
Talaris (TALS) Down on Patient Death From Renal Transplant Study